Handling Missing Data in Participants with a Baseline but No Post-baseline Data
Mallinckrodt, C. H.; Lipkovich, I.; Dickson, S.; Hendrix, S. B.; Molenberghs, G.
Show abstract
Clinical trial participants who are randomized to treatment and have a baseline value but no post-baseline data pose a unique challenge. These patients need to be included to preserve randomization. However, there is no information about the outcome or the intercurrent events that led to missing data. Composite and hypothetical strategies can accommodate participants with no post-baseline data. The present study investigated common methods based on hypothetical strategies in example data sets and in a simulation study. Because there is no information about the treatment effect when there is no post-baseline data, it is not surprising that various models yielded similar results. In simulated data, treatment contrasts were not biased when the reason for missing all post-baseline data was random, treatment related, or outcome related. Bias occurred only when missingness was treatment and outcome related, and arose from a missing not at random mechanism. The bias was not large. The maximum Type I error rate across all scenarios and methods was 6.4%. Imputing no change for missing data at the first postbaseline visit and assuming missing at random for all other missing values yielded a maximum Type I error rate of 5.1%. Given the idiosyncratic nature of clinical trials, no universally best analytic approach exists for dealing with participants that have a baseline but no post-baseline data. Analysts can choose among these methods to provide an approach tailored to the situation at hand.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Using numerical modelling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample 96%
- Using the Bayesian credible subgroups method to identify populations benefiting from treatment: An application to the Look AHEAD trial 94%
- Analysis of clinical trial registry entry histories using the novel R package cthist 94%
Similar papers in this journal
- Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial 96%
- Graphing and reporting heterogeneous treatment effects through reference classes 93%
- Machine learning for randomised controlled trials: identifying treatment effect heterogeneity with strict control of type I error 93%
Similar papers in this journal
- Vaccine safety surveillance using routinely collected healthcare data – An empirical evaluation of epidemiological designs 92%
- Simulating clinical trials for model-informed precision dosing: Using warfarin treatment as a use case 90%
- A systematic review of utilisation of diurnal timing information in clinical trial design for Long QT syndrome 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.